Objective: The aim of this study is to determine species-level distribution and antimicrobial resistance rates of bacteria of the genus Enterobacter isolated from various clinical specimens in a tertiary hospital.

Methods: In our study, the results of various clinical specimens in which the growth of Enterobacter was detected after culture in a six-year period within 2016-2021 were retrospectively analyzed over the laboratory information system.

Results: A total of 700 Enterobacter isolates were included in the study. Enterobacter cloacae (85%) was this study’s most frequently isolated agent. Bacteria of Enterobacter genus were most frequently produced in urine samples (42%). In E. cloacae, E. asburiae, and E. kobei isolates, 3%, 4%, and 4% resistance against amikacin and 5%, 6%, and 4% resistance against gentamicin were detected, respectively. 4% resistance to ciprofloxacin and trimethoprim-sulfamethoxazole was detected in E. asburiae isolates. E. cloacae, E. asburiae, and E. kobei isolates had 26%, 20%, and 18% resistance rates against ertapenem, respectively; lower rates of resistance were found for imipenem and meropenem.

Conclusion: Antimicrobial resistance data may show regional differences. In our study, low resistance rates were detected against various antibiotics such as aminoglycosides, imipenem, meropenem, ciprofloxacin, and trimethoprim-sulfamethoxazole. However, we recommend seeing the antimicrobial susceptibility results when choosing aztreonam, ertapenem, piperacillin-tazobactam, or third-generation cephalosorins for infections caused by Enterobacter isolates.